Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Fluorouracil vs Fluorouracil Plus Calcipotriene in Multiple Actinic Keratoses
NCT06851507Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of calcipotriol in actinic keratosis (AK) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Percent of patients approached and screened who enroll at 1 year. Started Oct 2025; status: active, not recruiting.
02
Drugs
calcipotriol
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT06851507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851507.